Intriguingly, based on work done predominantly using the mouse and the zebrafish as models, it now appears that there may be a role of VEGF and its receptors in many different aspects of cardiovascular development, including stem cell differentiation into cardiomyocytes, stem cell migration and survival, and heart development. [4] [5] [6] On the premise that cardiomyocytes express VEGF receptors 7 and that VEGF triggers the activation of mitogen-activated protein kinases, 8 a role for VEGF has also been shown in inducing the adult cardiomyocyte to re-enter the cell cycle, thus promoting cell division in the heart and determining the appearance of cardiac hypertrophy in response to pathological (pressure overload) and physiological (exercise) stimuli. 9 Finally, it has been shown that VEGF, even without pressure overload, can induce cardiomyocyte caryokinesis (increased number of cardiomyocyte nuclei) in vivo, e.g. after direct intramyocardial injection of a plasmid encoding human recombinant VEGF in a pig model of chronic myocardial ischaemia, in the absence of cytokinesis (increased number of cell divisions, leading to increased number of cardiomyocytes). 10 These observations suggest a role for VEGF in determining the physiological growth of the post-natal heart, even without the induction of true cardiomyocyte regeneration.
Despite the growing number of observations on putative roles for VEGF as a cardiac transcriptional regulator, a highly relevant issue in this area is to decipher VEGF pathway(s) that control pathological and physiological hypertrophy, aiming at inhibiting the former and augmenting the latter. Understanding how VEGF may actually reversenot induce-hypertrophic cardiomyopathy, a disease condition characterized by pathological myocardial hypertrophy secondary to pressure overload or to a large number of gene mutations affecting the cardiac contractile apparatus, and restore cardiac contractile function that is impaired in this condition has been the focus of the research by Zhou et al.
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Although it was originally thought that in the heart VEGFR-2, or KDR, is expressed predominantly in endocardial cells, more recent studies suggest that VEGF/KDR signalling also influences the embryonic development of cardiac muscle. 12 Cell fate lineage-marking experiments with the Rosa26-LacZ reporter mouse strain and a Cre (causes recombination) recombinase gene targeted to the KDR locus (i.e. a transgenic mouse strain expressing Cre recombinase in endothelial cells under the transcriptional control of the gene encoding KDR, cross-bred with the Rosa26 reporter strain, which expresses LacZ following Cre-mediated recombination) have demonstrated that KDR þ progenitor cells give rise to both cardiomyocytes and skeletal myocytes. 13 Furthermore, studies in the mouse embryo and mouse embryonic stem cell differentiation models have provided evidence that three lineages-endothelial cells, smooth muscle cells, and cardiomyocytes-develop from a common KDR þ cardiovascular progenitor.
14 The essential role of VEGF/KDR signalling in the initial stages of cardiovascular development is also suggested by the observation that KDR null embryos die at the stage of 6-8 somite pairs, even earlier than VEGF 2/2 embryos. 15 The death in these animals is the result of a failure of mesodermal and endodermal progenitors to differentiate into the vascular endothelium, the endocardium, and the myocardium.
instead as a decoy receptor that modulates the amount of VEGF available to KDR for KDR-dependent functions. 16 Mice lacking the Flt-1 tyrosine kinase domain, but still expressing the extracellular and transmembrane domains, develop a normal cardiovascular apparatus, suggesting that Flt-1 signalling is not essential during development and that the extracellular domain of Flt-1 acts indeed by modulating the amount of VEGF binding to KDR. 17 Zhou et al. 11 report on the effect of copper (Cu) supplementation on cardiac hypertrophy and on changes in the ratio of Flt-1 to KDR in copper-induced regression of phenylephrine-induced hypertrophy in cultured cardiomyocytes. Here, copper addition at a physiologically relevant level (5 mM final concentration for 24 h) did not change Flt-1 density, but markedly reduced KDR density in hypertrophic cardiomyocytes. Gene silencing of KDR in the absence of copper addition also reversed phenylephrine-induced cardiomyocyte hypertrophy. Gene silencing of Flt-1, conversely, blocked copper-induced regression of cell hypertrophy. The effect of Flt-1 on cardiac hypertrophy was mediated by the activation of a cGMP-dependent protein kinase-1 signalling pathway. Copper did not cause any change in VEGF production, but-through the changes described-altered VEGF signalling and increased the ratio of Flt-1 to KDR, thus inducing regression of cardiomyocyte hypertrophy.
This study confirms, but also significantly extends, previous observations by other groups 18, 19 and reinforces the hypothesis of an important role of VEGF signalling in regulating myocardial responses to haemodynamic forces, such as pressure overload, and also on physiological and pathological changes in cardiomyocytes. The signalling switch with a prevalence of Flt-1 over KDR has the potential to reduce cardiac responses to pressure overload and to mediate the appearance of an anti-remodelling phenotype. This is an important research line for at least two reasons. First, it provides new insights into the pathways controlling cardiac gene expression, yielding one of the first demonstrations of an active signalling role for Flt-1, which acts not onlyas previously mostly believed-as a VEGF scavenger averting KDR signalling in cardiomyocytes. From this standpoint, it would also be of interest to identify additional cofactors for VEGF receptors and to investigate their potential roles in cardiac gene expression during early and late stages of development and in disease conditions. Secondly, and more practically relevant, it might lead to the development of novel therapies against cardiac hypertrophy through pharmacological (e.g. dietary copper supplementation at doses that can be found in conventional multiple mineral supplements) or molecular biological strategies. Should similar effects of copper supplementation be found in controlled studies in patients, this might pave the road to a simple, non-toxic, and cheap therapy for hypertrophic cardiomyopathy. Figure 1 A schematic representation of the cardiomyocyte VEGF signalling pathway. Flt-1 and KDR are the two major VEGF receptors. In cardiomyocytes, VEGF drives cardiac hypertrophy or its regression, depending on the prevalent binding to KDR or Flt-1, respectively. Copper (Cu) supplementation determines a switch in the VEGF signalling pathway, increasing the ratio of Flt-1 to KDR. By this mechanism, copper induces regression of cardiomyocyte hypertrophy. VEGF, vascular endothelial growth factor; Flt-1, FMS-like tyrosine kinase-1; KDR, kinase insert domain receptor; PKG-1, cGMP-dependent protein kinase-1; Cu, copper; DAG, diacylglycerol; IP3, inositol trisphosphate; Sos, Son of Sevenless; Shc, Src-homology collagen protein; Grb-2, growth factor receptor-bound protein 2; MEK1/2, mitogen activated protein kinase (MAPK)/extracellular-regulated kinase (ERK) kinase 1/2; PKC, protein kinase C; PLC-g, phospholipase C-g; PD98059 (PD) and UO126 are selective ERK1/2 inhibitors.
